Malaria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Malaria is an acute febrile illness
that arises from the transmission of Plasmodium parasites through the bites of
infected female Anopheles mosquitoes. In humans, five parasite species are
capable of causing malaria, with P. falciparum and P. vivax posing the most
significant risk. P. falciparum is Africa's most prevalent and deadliest
parasite species, while P. vivax dominates in most countries outside of
sub-Saharan Africa. The onset of malaria symptoms, which include fever,
headache, and chills, usually occurs 10-15 days after the infective mosquito
bite. These symptoms can be mild and difficult to recognize as malaria.
However, if left untreated, P. falciparum malaria can quickly progress to
severe illness and death within 24 hours. Fever is a hallmark symptom of
malaria that is triggered by the release of parasites every 2 to 3 days,
depending on the Plasmodium species. High parasite burdens can result in severe
and life-threatening malaria, causing hemolysis and severe anemia, or end-organ
damage due to vascular adherence of infected erythrocytes and micro occlusion.
·
Annually, estimated 247 million cases of
malaria worldwide.
Thelansis’s “Malaria Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Malaria treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Malaria across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Malaria Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment